Luken Investment Analytics’s GSK GSK Stock Holding History

Luken Investment Analytics’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-101	Closed	-$3.6K	–	147
2023 Q2	$3.6K	Buy	+101	New	+$3.62K	﹤0.01%	135

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Luken Investment Analytics's GSK Position: Q3 2023 in Review

Luken Investment Analytics sold out of GSK (GSK) in Q3 2023, closing a stake of 101 shares — an estimated $3.6K sold.

Luken Investment Analytics first reported a position in GSK in Q2 2023 and held it in 1 quarter. The position peaked at $3.6K in Q2 2023. 846 funds tracked by Wall St. Rank hold GSK as of Q3 2023.

Luken Investment Analytics reported no remaining GSK position as of Q3 2023 after selling out during the quarter.
Luken Investment Analytics sold 101 GSK shares in Q3 2023, an estimated $3.6K.
Luken Investment Analytics first reported a position in GSK in Q2 2023 and held it in 1 quarter.
Luken Investment Analytics's GSK position peaked at $3.6K in Q2 2023.
846 funds tracked by Wall St. Rank held GSK as of Q3 2023.

Based on Luken Investment Analytics's 13F filing for Q3 2023, filed 11 Oct 2023.